Renal medicine and clinical pharmacy. (2020)

• Record Type: Book
• Further Information: Note: Rhiannon Braund, editor.
• Other Names: Braund, Rhiannon
• Contents: Intro -- Preface -- Contents -- Chapter 1: Introduction to Renal Pharmacy -- References and Further Information -- Comprehensive medical information on renal illnesses as well as other aspects of internal medicine can be found in: -- Comprehensive medical information that focuses on renal issues: -- Pharmacist specific information: -- Dosing guidance: -- Chapter 2: How Kidney Function Affects Drug Pharmacokinetics -- 2.1 Absorption -- 2.2 Distribution -- 2.3 Metabolism -- 2.4 Elimination -- 2.5 Catergorisation of Chronic Kidney Disease -- 2.6 Drug Dosing in Renal Impairment 2.7 Ageing and Renal Impairment -- 2.8 Dialysis -- 2.9 Drug Dosing in Dialysis -- 2.10 Pharmacokinetics and Pharmacodynamics -- Bibliography and Further References -- Chapter 3: Acute Kidney Injury: Pre-renal, Intra-renal and Post-renal -- 3.1 Pre-renal AKI -- 3.1.1 Anatomy and Physiology of the Kidney -- 3.1.2 Causes of Pre-renal AKI -- 3.1.3 Treatment of Pre-renal AKI -- 3.2 Intra-renal AKI -- 3.2.1 Glomerular Causes of AKI -- 3.2.2 Tubular Causes of AKI -- 3.2.3 Vascular Causes of AKI -- 3.2.4 Interstitial Causes of AKI -- 3.3 Post-Renal AKI -- 3.3.1 Anatomy of the Urinary Tract 3.3.2 Causes of Obstruction -- 3.3.3 Clinical Presentation -- 3.3.4 Management of Obstruction -- Bibliography -- Chapter 4: Chronic Kidney Disease and End Stage Renal Disease -- 4.1 Major Causes for Chronic Kidney Disease and Management -- 4.1.1 Diabetes -- 4.1.1.1 Epidemiology -- 4.1.1.2 Pathophysiology -- 4.1.1.3 Management -- 4.1.2 Hypertension -- 4.1.2.1 Epidemiology -- 4.1.2.2 Pathophysiology -- 4.1.2.3 Management -- 4.1.3 Polycystic Kidney Disease -- 4.1.3.1 Epidemiology -- 4.1.3.2 Pathophysiology -- 4.1.3.3 Management -- 4.1.4 Obstruction -- 4.1.4.1 Epidemiology 4.1.4.2 Nephrolithiasis (Kidney Stones) -- 4.1.5 Glomerulonephritis -- 4.1.5.1 ANCA Vasculitis -- 4.1.5.2 IgA -- 4.1.5.3 Lupus Nephritis (LN) -- 4.1.5.4 Membranous Nephropathy -- 4.2 Slowing the Progression and Protecting Existing Kidney Function Beyond Diabetes & Blood Pressure -- 4.2.1 Smoking Cessation -- 4.2.2 Exercise -- 4.2.3 Weight Reduction (Decrease in Proteinuria) -- 4.2.4 Obstructive Sleep Apnea Management -- 4.3 Anemia -- 4.3.1 Definition and Prevalence in CKD -- 4.3.2 Cause of Anemia in CKD -- 4.3.3 Clinical Impact and Complications in Patients and Therapeutic Goals -- 4.3.4 Iron 4.3.5 Erythropoiesis Stimulating Agents -- 4.3.6 Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitors (HIF-PHIs) -- 4.3.7 Treatment -- 4.4 Mineral Bone Disease -- 4.4.1 Definition and Prevalence in CKD -- 4.4.2 Cause of MBD -- 4.4.3 Clinical Impact and Complications in Patients and Therapeutic Goals -- 4.4.4 Phosphate Binders -- 4.4.4.1 Calcium Based Phosphate Binder -- 4.4.4.2 Non-calcium Based Binders -- 4.4.4.3 Iron Based Binders -- 4.4.4.4 Vitamin D -- 4.4.4.5 Calcimimetic -- 4.4.4.6 Treatment -- 4.5 Dyslipidemia and CKD -- 4.5.1 Introduction -- 4.5.2 Pathogenesis
• Publisher Details: Cham : Springer
• Publication Date: 2020
• Extent: 1 online resource
• Subjects: 616.6/106; Kidneys -- Diseases -- Treatment; Clinical pharmacology; Electronic books; Electronic books
• Languages: English
• ISBNs: 9783030376550; 3030376559
• Related ISBNs: 3030376540; 9783030376543
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.